Trabedersen
- Generic Name
- Trabedersen
- Drug Type
- Biotech
- CAS Number
- 925681-61-4
- Unique Ingredient Identifier
- 98OYR854NY
- Indication
Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
Phase 1
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 45
- Registration Number
- NCT06579196
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
Phase 2
Withdrawn
- Conditions
- Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Metastatic Lung Non-Small Cell Carcinoma
- Interventions
- Biological: AtezolizumabProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Electronic Health Record ReviewProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- University of Washington
- Registration Number
- NCT05935774
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Phase 3
Terminated
- Conditions
- Anaplastic AstrocytomaGlioblastoma
- Interventions
- Device: Drug delivery system for administration of AP 12009Procedure: Placement of Drug Delivery System
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Isarna Therapeutics GmbH
- Target Recruit Count
- 27
- Registration Number
- NCT00761280
- Locations
- 🇦🇷
FLENI, Ciudad Autónoma de Buenos Aires, Argentina
🇺🇸NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath